Table 2.
Tumor Genotype Versus Objective Clinical Response for All CD117+ Tumors
| Response | Genotype
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KIT 8
|
KIT 9
|
KIT 11
|
WT
|
KIT 13
|
KIT 17
|
PDGFRA 12
|
PDGFRA 18
|
|||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | |
| CR | 1 | 3.1 | 18 | 6.4 | 3 | 4.5 | 0 | 0.0 | ||||||||
| PR | 1 | 100.0 | 11 | 34.4 | 162 | 57.2 | 22 | 32.8 | 2 | 40.0 | 1 | 25.0 | 1 | 100.0 | 1 | 25.0 |
| SD | 12 | 37.5 | 53 | 18.7 | 19 | 28.4 | 1 | 20.0 | 2 | 50.0 | 2 | 50.0 | ||||
| PD | 3 | 9.4 | 18 | 6.4 | 12 | 17.9 | 1 | 20.0 | 1 | 25.0 | 1 | 25.0 | ||||
| NA | 5 | 15.6 | 32 | 11.3 | 11 | 16.4 | 1 | 20.0 | ||||||||
| Total | 1 | 32 | 283 | 67 | 5 | 4 | 1 | 4 | ||||||||
NOTE. Responses were reported for both confirmed and unconfirmed tumors from eligible patients.
Abbreviations: KIT 8, mutation of KIT exon 8; WT, wild type (no mutation of KIT or PDGFRA); CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not assessable.